This sector includes biotechnology, pharmaceuticals, research services, home healthcare, hospitals, long-term care facilities, and medical equipment and supplies. Companies in this sector include Astra Zeneca, Pfizer and Roche Holding.
Acadia falls on negative trial result in schizophrenia – US biotech Acadia Pharmaceuticals (Nasdaq: ACAD) saw its stock fall by 15% today on the back of a negative top-line result from its 396-patient “Enhance” Phase III study of Nuplazid (pimavanserin) in treatment resistant schizophrenia. The company, which is a mid-size holding of the UK’s International Biotechnology […]
Genmab raises $582m in Europe’s largest ever Nasdaq IPO – Denmark’s Genmab has raised a gross total of $582m from its US IPO, the largest sum ever by a European biotech. Genmab, which is already listed on Nasdaq Copenhagen, sold 32.78m ADSs – each of which represents one-tenth of a share – at $17.75/ADS, only a 3% […]
Silence stock jumps on Mallinckrodt deal – UK biotech Silence Therapeutics saw its stock jump by 60% this morning on the back of a licensing deal, R&D collaboration and equity investment from the Irish-domiciled, US-based speciality pharmaceutical group Mallinckrodt. The overall deal has a “biodollar” or headline value exceeding $2.1bn, although initially it provides an upfront […]
BB Healthcare announces first half results and new chairman – BB Healthcare (BBH)’s chairman, professor Justin Stebbing, has stepped down from his role due to his other commitments, it has been announced. He will remain at the company in the capacity of non-executive director and will be succeeded as chairman by Randeep Grewal (currently a […]
Scottish Mortgage leads $121m round in AI-based biotech Recursion – Baillie Gifford-managed Scottish Mortgage lnvestment Trust (SMT) has led a $121m Series C private financing in Recursion Pharmaceuticals, a US-based company that combines automated experimental biology with artificial intelligence tools. The financing brought in three new institutional investors – Intermountain Ventures, University of Minnesota, Texas […]
Trust favourite Gilead expands R&D deal with Galapagos – US biotech giant Gilead Sciences (NASDAQ: GILD) has entered into a ten-year R&D collaboration with Galapagos (Euronext/NASDAQ: GLPG) covering rights to the Belgium group’s entire development portfolio. The transformative deal includes a $3.95bn upfront payment – a new record in the industry – as well as $1.1bn in […]
Shield poised for FDA decision on Feraccru for anemia – Shield Therapeutics (STX) should hear at some point over the next two weeks whether the FDA will approve its oral iron supplement Ferracru for treatment of iron deficiency. The decision, due by 26 July, is of course important but is further complicated by a statistical issue with the […]
Morphosys takes option on Vivoryon’s QPCTL inhibitors in oncology – Germany’s Morphosys (MOR) has taken up an option to license Vivoryon’s family of inhibitors of the glutaminyl-peptide cyclotransferase-like (QPCTL) protein in oncology, in exchange for a commitment to invest €15m as part of a capital raising planned for later this year. The option covers Vivoryon’s lead compound […]
Y-mAbs confirms plans to start naxitamab filing in November – HBM-investee Y-mAbs Therapeutics (YMAB) has confirmed plans to start a rolling US filing for naxitamab for the treatment of patients its with relapsed/refractory high-risk neuroblastoma in November, after a pre-BLA meeting with the FDA. The company aims to file the clinical/safety and non-clinical portions of […]
4D Pharma starts first trial in asthma – UK microbiome biotech 4D Pharma (DDDD) has started a clinical trial of a live biotherapeutic, MRx-4DP000, in asthma, the first time such a drug concept has been tested in this condition. The double-blind, placebo-controlled Phase I/II study will enrol 90 patients whose asthma is inadequately controlled on inhaled therapy. Patients will […]
Cantargia aism for first results of key study in Q4 – Sweden’s Cantargia (CANT) expects to report the first efficacy data from lead product nidanilimab in the fourth quarter of this year, some months earlier than expected, after quickly reaching its target recruitment of 20 patients – six with non-small cell lung cancer (NSCLC) and […]
FDA surprises with controversial OK for Karyopharm’s selinexor – US Biotech Karyopharm Therapeutics (Nasdaq:KPTI) saw its stock jump 36% yesterday on news that the FDA has granted an accelerated approval to its anticancer Xpovo (selinexor), a nuclear export inhibitor, for late-line relapsed or refractory multiple myeloma (RRMM). The news surprised many specialist investors as the application […]
Oncimmune expands network with EarlyCDT Lung deal with Russia’s R-Pharm UK biotech Oncimmune (ONC) has expanded its distribution network for its lead product, the EarlyCDT Lung liquid biopsy test, with the signing of a deal with Russia’s R-Pharm JSC. The deal comes a week after Oncimmune announced an agreement with the US company, Biodesix, to commercialise the […]
Sweden’s Calliditas Therapeutics raises SEK210m Sweden’s Calliditas Therapeutics (Nasdaq Stockholm: CALTX) has raised SEK210m in a directed share issue of 3,505,291 shares at a price of SEK 60 per share, to domestic and international investors, including the US specialist investor BVF Partners, whcih invested $12m (cSEK112m) in the placing. At the same time, three of […]
Morphosys receives milestone as GSK advances RA antibody – German biotech MorphoSys (NASDAQ: MOR), a holding of International Biotechnology Trust (IBT), has received a €22m milestone payment from its licensing partner GlaxoSmithKline (GSK) in connection with the start of a Phase III trial programme with otilimab (formerly MOR103/GSK3196165) in rheumatoid arthritis (RA). GSK will conduct four […]
Y-mAbs Therapeutics confirmed BLAs on track for this year – HBM Healthcare-portfolio company Y-mAbs Therapeutics (Nasdaq: YMAB) has confirmed it remains on target to file regulatory submissions for both of its rare paediatric cancer products this year. The company confirmed it is on track to file for omburtamab for the treatment of CNS/LM from neuroblastoma, […]
Sareum raises £0.8m to advance TYK2/JAk1 programmes Sareum Holdings (SAR) has raised £0.78m through a placing of 195m shares at 0.4p per share, in a move principally designed to progress its TYK2/JAK1 programmes. As a result of the placing, the company will have 3.07bn shares in issue. The funds Sareum to advance its internal programmes – SDC-1801 […]
Syncona sells Blue Earth Diagnostics to Bracco Imaging – Syncona has reached an agreement to sell Blue Earth Diagnostics to Bracco Imaging, a global leader in diagnostic imaging for $450 million (GBP354.3 million) plus closing adjustment estimated at $25 million (GBP19.7 million). The sale delivers a 10.0x multiple, including prior distributions, on invested capital for Syncona […]
AbbVie to buy Allergan in a $63bn deal US pharma giant AbbVie is to acquire the US-based, but Irish-domiciled speciality pharma Allergan, in a cash-and-share deal with an equity value of $63bn. he transaction is designed to expand and diversify AbbVie’s revenue base into new therapeutic areas, including what is termed medical aesthetics – Allergan […]
BMS’s plan to dispose of Otezla puts focus on putative TYK2i class Bristol-Myers Squibb has announced plans to divest the anti-inlammatory drug Otezla (apremilast) – which it would ostensibly obtain in its pending merger with Celgene – seemingly to allay anti-trust concerns over new oral treatments for psoriasis. The move is likely to be of […]
Trust favourite Vertex holds industry’s most valuable R&D asset Investment trust favourite Vertex Pharmaceuticals (Nasdaq: VRTX) holds the pharma/biotech industry’s most valuable R&D asset, according to calculations from the industry consultancy Evaluate. The US firm’s triple therapy of VX-445/tezacaftor/ivacaftor, which is in Phase III studies for cystic fibrosis and on track for a launch next […]
Incyte details positive outcome of topical rux in vitiligo Trust favourite Incyte (Nasdaq:INCY) saw its stock rise by 5% today after reporting positive results of a Phase II study of ruxolitinib cream in the treatment of vitiligo (a condition characterised by de-pigmentation of skin) at a scientific conference over the weekend. Incyte, which is held by […]
Syncona to step up capital deployment after great year – Syncona has announced a whopping 37.9% return on NAV for the year ended 31 March 2019. It has transformed its portfolio so that life sciences investments now account for £1.06bn of the fund’s £1.46bn NAV. Some highlights: foundation of three highly innovative portfolio companies OMASS Therapeutics […]
In QuotedData’s other news 6 June 2019: Regional REIT has announced the sale of an office building in Sheffield at a price 25% higher than when it was last valued. Bought in 2016 for £6.3m, Aspect Court, Pond Hill, Sheffield was sold to Sheffield Hallam University for £8.8 million, reflecting a net initial yield of 6.6%. […]
InflaRx stock crashes on study failure in HS US-listed German biotech InflaRx (Nasdaq: IFRX) saw its stock fall by 89% earlier today on the failure of a Phase IIb study of its lead product, IFX-1, in moderate to severe hidradenitis suppurativa (HS), a painful and chronic inflammatory skin disease. The study enrolled 179 patients who […]
Verona Pharma starts Phase II of MDI-delivered ensifentrine in COPD Verona Pharma, the dual AIM (VRP) and Nasdaq (VRNA)-listed biotech specialising in respiratory disease, has started a Phase II dose-ranging trial of a metered-dose inhaler (MDI) formulation of its lead product ensifentrine in moderate-to-severe chronic obstructive pulmonary disease (COPD). The trial is randomised, double-blind and […]
Promising early clinical data on Sareum’s SRA737 presented at ASCO Sierra Oncology, the licence holder for the Sareum (SAR)-originated SRA737, presented positive preliminary data from its two Phase I/II studies at the 2019 Annual Meeting of the American Society of Clinical Oncology (ASCO) conference over the weekend. The poster presentations cover preliminary clinical data from […]
Genmab finally sets sights on Nasdaq Denmark’s Genmab, which has the distinction of being Europe’s largest biotech by market cap (DKK71.9bn/$10.7bn) and has filed with the US SEC to raise $500m through a US IPO of American depositary shares (ADS) on Nasdaq. The move is notable both for the proposed offering’s size as well as […]
BioPharma Credit makes new loan to BioDelivery Sciences – BioPharma Credit has entered into a senior secured term loan agreement for up to US$80 million with BioDelivery Sciences International, Inc. (Nasdaq: BDSI), a commercial-stage specialty pharmaceutical company with a current market capitalisation of approximately US$400 million. In addition, BioPharma Credit bought 5,000,000 BDSI shares at […]
Biotech Growth extends run of poor performance – On Friday, Biotech Growth Trust published results for the year ended 31 March 2019. Its net asset value per share rose by 5.3% and the share price by 4.6%, reflecting a slight widening in the discount. The benchmark (Nasdaq Biotechnology Index) returned 13.0%. Biotech Growth Trust has now […]
Please review our cookie, privacy & data protection and terms and conditions policies and, if you accept, please select your place of residence and whether you are a private or professional investor.
Due to data protection policies, USA residents can not access our data.
Your content has been curated